WallStSmart

Merck & Company Inc (MRK)vsTruBridge Inc. (TBRG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 19145% more annual revenue ($66.57B vs $345.90M). MRK leads profitability with a 4.8% profit margin vs 1.3%. TBRG appears more attractively valued with a PEG of 0.32. TBRG earns a higher WallStSmart Score of 45/100 (D).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

TBRG

Hold

45

out of 100

Grade: D

Growth: 3.3Profit: 4.5Value: 7.3Quality: 6.0
Piotroski: 5/9Altman Z: 1.57
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-77.2%)

Margin of Safety

-77.2%

Fair Value

$83.04

Current Price

$148.10

$65.06 premium

UndervaluedFair: $83.04Overvalued
TBRGUndervalued (+68.9%)

Margin of Safety

+68.9%

Fair Value

$60.68

Current Price

$26.24

$34.44 discount

UndervaluedFair: $60.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

TBRG2 strengths · Avg: 9.0/10
PEG RatioValuation
0.3210/10

Growing faster than its price suggests

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

TBRG4 concerns · Avg: 3.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.574/10

Distress zone — elevated risk

Market CapQuality
$391.33M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : TBRG

The strongest argument for TBRG centers on PEG Ratio, Price/Book. PEG of 0.32 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : TBRG

The primary concerns for TBRG are EPS Growth, Altman Z-Score, Market Cap. A P/E of 90.0x leaves little room for execution misses. Thin 1.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

TBRG carries more volatility with a beta of 1.29 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TBRG scores higher overall (45/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

TruBridge Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

TruBridge, Inc. provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. The company is headquartered in Mobile, Alabama.

Visit Website →

Want to dig deeper into these stocks?